INTRODUCTION
Symptomatic fibroids are disabling and associated with significant morbidity that affects approximately 20-40% of women of childbearing age. 1 The most common symptom of uterine fibroids for which treatment is sought is heavy or prolonged menstrual bleeding, which may result in iron deficiency anemia. 2 When symptoms progress and farmacotherapeutical options fail, surgical intervention may be necessary. During the last decade, Uterine Artery Embolization (UAE) has been greeted as a minimally invasive treatment alternative for surgery in reducing symptoms of heavy menstrual bleedings caused by fibroids. Several randomized controlled trials compared UAE with hysterectomy and/or myomectomy and found similarly good results for both interventions up to 24 months of follow-up. [3] [4] [5] [6] Earlier, we reported on the 2-year results from the EMMY (EMbolization versus hysterectoMY) trial and compared clinical results, 7 Health Related Quality Of Life (HRQOL) outcomes 8 and menopausal symptoms 9 between UAE and hysterectomy. After 2 years the chance to avoid a hysterectomy in the UAE group was 76.5% while menorrhagia and HRQOL improved significantly, similarly in both groups. Both UAE and hysterectomy affected ovarian reserve in women older than 45 years. Based on these 2-year follow-up results, UAE was considered to be a good alternative to hysterectomy. Because fibroids may grow back, menorrhagia can recur, or other symptoms warranting hysterectomy may emerge beyond the 2 years of follow-up period. Herefore, we observed up our cohort until 5 years after treatment and investigated clinical and HRQOL results between UAE and hysterectomy as well as outcomes between baseline and 5-year follow-up in patients from the EMMY trial.
METHODS

Study design
The EMMY study is a multicentre, randomized controlled trial that was conducted in the Netherlands. Patients who visited the gynecological outpatient clinics were invited to participate if they 1) were pre-menopausal, 2) were diagnosed with uterine fibroids, 3) had menorrhagia, 4) had no other treatment options than a hysterectomy and 5) had no desire for future pregnancy. After written informed consent was obtained, patients were allocated randomly (1:1) to UAE or hysterectomy. Randomization was computer-based and stratified for participating hospitals. The study was approved by the Central Committee Involving Human Subjects (www.ccmo.nl) and by local ethics committees of participating hospitals.
Procedures
UAE and hysterectomy were performed according to professional standards as described earlier (Table 1 ). 7;8 In the UAE group, ten patients (12.3%) underwent unilateral UAE. 7 Table 1 . Baseline and procedural characteristics 8 . Sample size and endpoints of the study
UAE N=88 N (%)
The sample size was based on the primary endpoint of the 2-year clinical study: the elimination of menorrhagia, thus avoiding hysterectomy after UAE in at least 75% of the patients after 2 years. 7 To reject the null hypothesis that UAE and hysterectomy are not clinically equivalent, at least 2 x 60 (=120) analyzable patients had to be included. 7 Endpoints after 5 years were re-interventions, menorrhagia, menopause and menopausal symptoms, quality of life, urinary and defecation function and satisfaction with the received treatment.
Study measures
Patients received questionnaires at baseline and at fixed intervals for 2 years after treatment. 8 In addition, for logistic reasons, all patients received 1 questionnaire in the autumn of 2007, at a median follow up period of approximately 5 years after primary treatment, which resulted in a variable follow-up in both groups. In tables and figures the median of 5 years is depicted as a fixed point in time for both treatment arms, despite this variation within the group. All questionnaires were identical, except for the 5-year questionnaire, which was a condensed version without the Higham Pictorial Chart, Euro-Quality of Life-5, Health Utilities Index Mark 3, sexual activity and body image questionnaires to optimize the response rate. [10] [11] [12] [13] [14] [15] The following subjects were evaluated in the 5-year questionnaire: additional interventions between 2-and 5-year follow up evaluation (in case of nonrespondents, the patients' general practitioners were contacted by telephone to check for any additional procedures), menstrual or 'very unsatisfied'. We also inquired whether patients would recommend the primary treatment to a friend. Finally, we asked women whether or not they would indeed have chosen the assigned treatment again if they had had the opportunity to do so.
Statistical analysis
Analyses were done using SPSS statistical software (version 16.0). Study outcomes were analyzed according to original treatment assignment (intention to treat). Re-interventions were also analyzed according to per-protocol analysis. A Kaplan Meier curve was constructed to show the distribution of the secondary hysterectomies over time. Differences in categorical data were compared with c 2 -tests or Fisher Exact tests, if appropriate. The Student t-test (or Mann-Whitney when applicable) assessed differences in numeric data.
A probability value of <0.05 was considered statistically significant. Predictors for failure
(secondary hysterectomy) were tested by logistic regression analysis. In this analysis, baseline characteristics (see appendix 1) were included for multiple regression analysis whenever univariate analysis revealed probability values < 0.1. In the multiple regression analysis, a p-value of <0.05 was considered statistically significant. 
Clinical outcome
Re-interventions: In addition to the 19 secondary hysterectomies (23.5%) that were performed in the UAE group in the first 2 years, 7 another 4 hysterectomies were required between 2 and 5 years, all because of insufficient improvement of bleeding complaints ( Figure 1 . Trial profile. in the hysterectomy group needed re-intervention (table 2) .
Bleeding characteristics: Table 3 shows various bleeding characteristics of the UAE group.
On average menorrhagia decreased over time. After 5 years, 67 out of 81 women (82.7%)
were either symptom-free (n=58) or reported great (n=4) or moderate (n=5) improvement.
Of the 58 women that still had their uterus after 5 years, 44 (75.9%) were symptom-free or reported great or moderate improvement; 8 women (13.8%) reported their menstrual bleeding to be unchanged compared with baseline. In this group, 10 women reported not to suffer from menorrhagia anymore because of menopause.
Menopause
Patients were asked the question: do you feel that you are in or beyond menopause? In the UAE group 34.6% of the women and in the hysterectomy group 47.1% of the women answered 'yes', which is significantly different (p=0.03). The mean Wiklund score for menopausal symptoms of both treatments is plotted over time in Figure 3 . Within group analysis revealed a significant increase in the hysterectomy group from baseline to 5 years (p=0.04). The UAE group did not show a significant increase (p=0.43). Repeated measurements analysis showed no differences between the groups after 5 years. 
Quality of life outcomes
Generic HRQOL Figures 4a and 4b display mental health (SF36-MCS) and physical health (SF36-PCS) scores
throughout the study period for both groups. Results of the 2-year follow-up evaluation were described earlier. 8 Repeated measurements analysis shows no differences between the groups during 5-year follow-up for both the MCS and PCS scores. Bold numbers indicate a statistically significant (p<0.05) change from baseline in the within-group analysis.
at baseline to 1.3% at 2 years). 8 However, after 5 years, an increased use of laxatives was found (13.3%). In the hysterectomy group this proportion was stable at 5.8%, with an increase after 5 years to 8.7%. After 5 years, 17.3% of women in the UAE group and 10.0%
of women in the hysterectomy group used incontinence pads (p=0.23). in the UAE versus 88.6% in the hysterectomy group (p=0.37, 
COMMENT
This article describes the results of a large, long-term, randomized trial that compared UAE with hysterectomy in the treatment of menorrhagia in the presence of uterine fibroids.
After a median of 5 years, 23 hysterectomies (28.4%) were performed in the UAE group, all because of uncontrolled menorrhagia. The success rate of 71.6% (or 76.5% after a technically successful UAE procedure) is comparable to prospective uncontrolled single arm UAE studies [23] [24] but lower than those reported in retrospective studies. [25] [26] [27] This may be explained by the fact that our patients could participate only in the EMMY study when severe bleeding complaints were present, while other treatment options had failed. In contrast to other studies, all our patients had a classic indication for hysterectomy and were indeed willing to undergo surgery. Because 82.6% (19/23) of the secondary hysterectomies in this study occurred within 2 years after UAE, not undergoing a hysterectomy in the first 2 years after UAE might be a predictor for being long-term hysterectomy-free. This corresponds to other data. 23 Some studies have pointed out that failure rates are likely to increase whenever bilateral embolization cannot be performed. 25;28 In our study, 10 women underwent unilateral UAE. Three of them eventually underwent a hysterectomy, all within 2-year followup. This percentage (3/10) of secondary hysterectomies is more or less the same as in bilateral embolization in this study-group, which does not underline the higher percentage of failure in unilateral embolization. Our finding that a high body mass index at baseline is a predictor for failure of UAE is a new finding that might be of importance when a patient is being counseled for UAE. However, the risk for obese patients to undergo surgery is extensive also. The gynecologist should balance the risks and benefits of both options with the individual patient.
Control of bleeding of women in the UAE group who still had their uterus after 5 years in our study was 75.9%. Although failure was strictly defined as a secondary hysterectomy, 12 patients in the UAE group still needed to use medication to remedy menorrhagia, and 8 of them showed no improvement of menorrhagia; these women are potential candidates for re-intervention. For this reason, we will approach them after another 5 years to establish the definitive long-term failure rate of UAE in this trial. Evidently even a hysterectomy does not guarantee an intervention-free life: in our study, 10.7% of patients in the hysterectomy group needed a re-intervention, most of them because of complications caused by the hysterectomy (adhesiolysis, a vesicovaginal fistula, or reconstruction surgery). Some studies even demonstrate that women after a hysterectomy are at higher risk for pelvic floor repair, 29 which underlines the re-intervention risk after a hysterectomy to be present. However, this
could not be found in our study; the UDI did not show a difference in complaints between the UAE and the hysterectomy group. Ovarian failure after UAE is a well-recognized complication that may result from inadvertent embolization of utero-ovarian collateral vessels. [30] [31] Earlier we showed both UAE and hysterectomy to affect ovarian reserve. 9 As a consequence, especially those women > 45 years old seem to be at higher risk than women without UAE/hysterectomy for becoming menopausal after both interventions. In our 5-year analysis, however, in the hysterectomy group, a higher percentage of patients reported subjectively to believe that they were beyond menopause than in the UAE group.
This might be explained by the absence of objective symptoms (i.e. menstrual periods) in women who had a hysterectomy and therefore might be biased, although it can provide an indication. The Wiklund score (evaluating the menopausal symptoms instead of bleeding)
did not show a difference in menopause between both groups after 5 years. Comparing HRQOL, we showed that the main increase in HRQOL occurred in the first months after treatment 8 and remained stable for 5 years without showing differences between the groups.
Hemoglobin level < 12.0 g/dL and age at baseline were predictive of PCS-increase;
worse physical condition at baseline (low hemoglobin and being older) predicted a higher increase in physical condition after 5 years. Apparently these patients had the most to gain in the long term. Higher age at baseline that predicted a worse physical condition probably reflects the normal decline in physical function that comes with age. For clinical practice, this substantiates that the best indication for treatment is heavy symptoms at baseline. Evident differences between the 2 groups in urinary function were not observed during the 5-year follow-up period; both groups showed a comparable improvement. A positive effect of hysterectomy on urinary function has been described before 32 ; the positive effect of UAE on urinary function, however, is a new finding. Defecation function only improved in the UAE group. After 5 years, this group had a significantly better defecation function than the hysterectomy group, which did not show an increase or a decrease in defecation function.
The positive effect of UAE on defecation function is another new finding that has not been described before. The increasing use of laxatives in the UAE group from 1.3% to 13.3% is a very contradictory finding. The possible effect of adhesion formation to the colon described after UAE might explain this. 33 Additionally, the subjective change in overall quality of defecation, compared with baseline, was not reported to be different between both groups, which makes the huge difference in (the objective) DDI after 5 years difficult to ground.
From 2 years onward, in both groups, a mild but not significant deterioration in urinary and defecation function was found, which probably can be ascribed to the effect of increasing age on the prevalence of pelvic floor dysfunction. 34 The number of fibroids appeared to be the only predictor for UDI improvement, which probably is explained by the mechanical effect of enlarged fibroid uteri. Satisfaction, treatment preference (for the received treatment) and recommendation of the received treatment to a friend were all similarly good in both groups without differences between them, which confirms earlier findings. 35 These findings support that patients perceive both treatments alternatives as acceptable options. Despite the accumulating beneficial evidence from randomized trials, the implementation of UAE as an alternative to hysterectomy in gynecological practice is relatively slow. In Europe it is estimated that < 5% (Cardiovascular and Interventional Radiological Society of Europe survey 2008, unpublished data) potential UAE candidates are being offered this alternative, and most women who undergo UAE seem to be those who discovered this alternative to surgery through the Internet. In conclusion, UAE is a proven valuable treatment alternative for surgery in women with symptomatic uterine fibroids. In view of the currently available evidence, the time is ripe to counsel all women who are candidates for hysterectomy for their symptomatic fibroids on the possibility of UAE. In 5 years, in 71.6% of all women that underwent UAE, a hysterectomy was avoided, and there was no difference in HRQOL between groups. Besides this, one has to keep in mind that there might be a chance that, instead of a hysterectomy, a less invasive intervention or the use of medication may be needed, which is reflected in the number of patients that reported their menorrhagia complaints as unchanged compared with baseline. However, because these women chose not to have a secondary hysterectomy so far, the chance would only increase that they would continue not to request one in de future. The mean age of our patient group is 50 years now, and menopause is looming. Of course, this is not a certainty and can be certified only by observation of this patient group until menopause.
APPENDIX 1
Predictors for failure Effect of baseline-variables on HRQOL 
